Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Defense Advanced Research Projects Agency (DARPA) has awarded $3.8m contract, as part of its Dialysis-Like Therapeutics (DLT) program, to CytoSorbents to develop new broad-spectrum, porous polymer capable of removing cytokines, toxins and certain biowarfare agents from whole blood and treating sepsis.
Subscribe to our email newsletter
Based on the achievement of pre-determined milestones, the company will receive $1.5m in funding for the first of five years.
In addition, DARPA is funding for the development of a portable, artificially intelligent blood purification system that can detect and remove, in real time, substances that can contribute to sepsis.
CytoSorbents chief executive officer Phillip Chan said under the DARPA program, the company is looking to advance its polymer technologies to not only remove cytokines, but also various toxins, and do so with little to no anti-coagulation in both high flow and microfluidic systems.
"We are one of the industry leaders in the area of blood purification to treat sepsis and other critical care illnesses, with our first-in-class CytoSorb cytokine filter currently approved and commercialized in the European Union," Chan added.
"Our porous polymers are ideally suited to achieve the broad spectrum removal that is needed to counter most of these agents.
"Therapies like CytoSorb and the device being proposed by DARPA are sorely needed and we are proud to be part of this worthy effort."